IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
IOVANCE BIOTHERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Amtagvi | $220.02M | $103.57M | – | 83.5% | +112.4% |
| Proleukin | $43.48M | $60.50M | $1.19M | 16.5% | -28.1% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $259.01M | $161.04M | $0 | 98.3% | +60.8% |
| Non-US | $4.49M | $3.03M | $1.19M | 1.7% | +48.3% |
From the segment and revenue-disaggregation notes of Iovance Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.